BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/28/2021 9:18:59 AM | Browse: 394 | Download: 1084
 |
Received |
|
2020-12-29 05:48 |
|
Peer-Review Started |
|
2020-12-29 09:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-11 13:02 |
|
Revised |
|
2021-10-14 14:11 |
|
Second Decision |
|
2021-12-24 04:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-24 08:22 |
|
Articles in Press |
|
2021-12-24 08:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-12-14 09:57 |
|
Typeset the Manuscript |
|
2021-12-26 15:43 |
|
Publish the Manuscript Online |
|
2021-12-28 09:18 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
You-Wen Tan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the social development project of Jiangsu Province |
BE2020775 |
| Medical Project of Health Department Jiangsu Province |
H201802 |
|
| Corresponding Author |
You-Wen Tan, MD, Chief Doctor, Professor, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Danjiamen 300,runzhouqu,zhenjiang, Zhenjiang 212003, Jiangsu Province, China. tyw915@sina.com |
| Key Words |
Tyrosine kinase inhibitors; Nilotinib; Chronic myelogenous leukemia; Hyperbilirubinemia; Drug induced liver injure; Liver injury |
| Core Tip |
Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. Nilotinib-induced hyperbilirubinemia manifests usually as indirect bilirubinemia without observation of elevated alanine aminotransferase or aspartate aminotransferase levels. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, in the absence of elevated levels of liver enzymes or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. |
| Publish Date |
2021-12-28 09:18 |
| Citation |
Tan YW. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia? World J Meta-Anal 2021; 9(6): 488-495 |
| URL |
https://www.wjgnet.com/2308-3840/full/v9/i6/488.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v9.i6.488 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
